Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
NeurogeneNGNE | Open-market sale10b5-1 plan | 05/06 | 05/08 | 9,600 sh2 trades | $31.26avg. | $300,048 | −9.3% | |
Christine Mikail CvijicPresident and CFO | NeurogeneNGNE | Open-market sale10b5-1 plan | 03/26 | 03/30 | 2,558 sh | $21.62 | $55,303.96 | −2.4% |
NeurogeneNGNE | Open-market sale10b5-1 plan | 03/26 | 03/30 | 3,352 sh | $22.07 | $73,978.64 | −0.2% | |
Julie JordanChief Medical Officer | NeurogeneNGNE | Open-market sale10b5-1 plan | 03/26 | 03/30 | 828 sh | $21.89 | $18,124.92 | −6.2% |
NeurogeneNGNE | Open-market sale10b5-1 plan | 03/13 | 03/17 | 4,045 sh3 trades | $20.81avg. | $84,177.55 | −3.7% | |
NeurogeneNGNE | Open-market sale10b5-1 plan | 03/13 | 03/17 | 6,797 sh3 trades | $20.81avg. | $141,445.87 | −18.2% | |
Christine Mikail CvijicPresident and CFO | NeurogeneNGNE | Open-market sale10b5-1 plan | 02/27 | 03/03 | 4,800 sh | $25.11 | $120,528 | −4.2% |
Stuart CobbChief Scientific Officer | NeurogeneNGNE | Open-market sale10b5-1 plan | 25/05/14 | 25/05/15 | 6,797 sh | $15.15 | $102,974.55 | −24.6% |
Christine Mikail CvijicPresident and CFO | NeurogeneNGNE | Open-market sale10b5-1 plan | 25/03/13 | 25/03/17 | 4,501 sh | $16.94 | $76,246.94 | −5.9% |
NeurogeneNGNE | Open-market buy | 24/11/26 | 24/11/27 | 48,770 sh4 trades | $25.83avg. | $1,259,622.58 | +2.9% | |
NeurogeneNGNE | Open-market buy | 24/11/26 | 24/11/27 | 48,770 sh4 trades | $25.83avg. | $1,259,622.58 | +2.9% | |
NeurogeneNGNE | Open-market buy | 24/11/26 | 24/11/27 | 48,770 sh4 trades | $25.83avg. | $1,259,622.58 | +2.9% | |
Christine Mikail CvijicPresident and CFO | NeurogeneNGNE | Open-market buy | 24/11/22 | 24/11/25 | 24,000 sh | $20.48 | $491,520 | +45.4% |
NeurogeneNGNE | Open-market buy | 24/11/22 | 24/11/25 | 47,500 sh | $20.40 | $969,000 | +3.8% |